Nivalis Therapeutics Company Profile (NASDAQ:NVLS)

Analyst Ratings

Consensus Ratings for Nivalis Therapeutics (NASDAQ:NVLS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.50 (533.05% upside)

Analysts' Ratings History for Nivalis Therapeutics (NASDAQ:NVLS)
Show:
DateFirmActionRatingPrice TargetActions
5/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2015HC WainwrightReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2015Robert W. BairdReiterated RatingPositive$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2015Stifel NicolausInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Nivalis Therapeutics (NASDAQ:NVLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
5/2/2016Q1 16($0.44)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4 15($0.36)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2015Q3 15($0.42)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/18/2012$0.61$0.61ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012$0.47$0.73ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/26/2011$0.68$0.73ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/11/2011$0.77$0.79ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2011$1.03$1.04ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2011$0.94$1.03ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nivalis Therapeutics (NASDAQ:NVLS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Nivalis Therapeutics (NASDAQ:NVLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nivalis Therapeutics (NASDAQ:NVLS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/5/2016David Malcom RodmanCMOSell5,950$4.66$27,727.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2016Jon CongletonCEOBuy5,000$3.87$19,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2016Jon CongletonCEOBuy5,000$4.22$21,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Jon CongletonCEOBuy5,000$4.38$21,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Jon CongletonCEOBuy5,000$8.10$40,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Robert E ConwayDirectorBuy10,000$8.10$81,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015James E FlynnInsiderBuy250,000$14.00$3,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Bay Master Investors (C HawkesMajor ShareholderBuy17,200$14.69$252,668.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Bay Master Investors (C HawkesMajor ShareholderBuy20,400$14.47$295,188.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Global Healthcare Mas JennisonMajor ShareholderBuy26,149$14.00$366,086.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nivalis Therapeutics (NASDAQ:NVLS)
DateHeadline
07/14/16 09:06 AMNivalis Therapeutics To Present At JMP Securities Conference; Webcast At 1:30PM
07/08/16 08:30 AMNivalis Therapeutics files for $142.5M shelf registration
07/07/16 06:11 AMNivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis - [at noodls] - - Study is Evaluating N91115 in Patients Homozygous for the F508del-CFTR Mutation and Being Treated with Orkambi™ - 'Cavosonstat' Approved as the Unique Non-proprietary or Generic Name for N91115 - Data ...
07/06/16 03:31 PMNivalis Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - BOULDER, Colo., July 06, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis ('CF'), today announced ...
06/15/16 06:19 AMNivalis Therapeutics to Present at the JMP Securities Life Sciences Conference - [at noodls] - BOULDER, Colo., June 15, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis ('CF'), today announced ...
06/10/16 04:01 PMNivalis Therapeutics, Inc. :NVLS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/01/16 06:23 AMNivalis Therapeutics to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - BOULDER, Colo., June 01, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis ('CF'), today announced ...
05/16/16 03:22 PMNivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis - [at noodls] - - Study to Evaluate N91115 in Patients Heterozygous for F508del-CFTR and a Gating Mutation - Data Expected in the First Half of 2017 BOULDER, Colo., May 16, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, ...
05/03/16 01:48 PMEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q1 Earnings Report - Below are the earnings highlights for Nivalis Therapeutics, Inc. (NVLS): -Earnings: -$7.84 million in Q1 vs. -$4.31 million in the same period last year. -EPS: -$0.51 in Q1 vs. -$1.95 in the same period last year.
05/02/16 04:27 PMNivalis Therapeutics reports 1Q loss -
05/02/16 03:20 PMNivalis Therapeutics Reports First Quarter 2016 Financial Results - [at noodls] - - Two Phase 2 Studies in Cystic Fibrosis Now Enrolling BOULDER, Colo., May 02, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical-stage pharmaceutical company focused on treating ...
04/22/16 03:32 PMNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta -
04/22/16 03:16 PMNivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - [at noodls] - BOULDER, Colo., April 22, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis ('CF'), today announced ...
04/19/16 02:01 PMNivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery - BOULDER, Colo., April 18, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced the appointment of David Rodman, MD as chief medical ...
04/18/16 07:22 AMNivalis Therapeutics Names David Rodman As Chief Medical Officer - Nivalis Therapeutics Inc (NASDAQ: NVLS) hired David Rodman as its chief medical officer and executive vice president of discovery. Until recently, he was the CMO and EVP of R&D at miRagen Therapeutics. Nivalis Therapeutics indicated Rodman would lead the discovery and clinical development strategy and operations. That included advancement of N91115, its lead investigational drug and first-in-class stabilizer of the cystic fibrosis transmembrane conductance ...Full story available on Benzinga.com
04/09/16 01:36 PMRecently Changed Price Targets On Nivalis Therapeutics, Inc. (NVLS) - 0 shares were traded on Nivalis Therapeutics, Inc.'s last session. The firm has price to sales ratio of 0.11 and its price to book per share was 0.51. Nivalis Therapeutics, Inc. had its "outperform" rating reiterated by analysts at Robert W. Baird.
04/06/16 01:47 PMThe U.S. Gets 2nd Biosimilar, ORMP Awaits Data This Qtr, PFE Hits Mark In OPAL - IRWD closed Tuesday's trading at 10.79, down 3.92%. Nivalis Therapeutics Inc. (NVLS) has reached the halfway point in dosing of the 135 patient phase II trial of N91115 in cystic fibrosis. The study is evaluating two doses of N91115, 200mg and 400mg ...
04/05/16 07:20 AMNivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis - [at noodls] - Company on track to report results from the study in fourth quarter this year BOULDER, Colo., April 05, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical ...
04/05/16 07:00 AMNeed for Patient-Centric Clinical Trials Fuels Adoption of Greenphire's ClinCard Solution - [PR Newswire] - KING OF PRUSSIA, Pa., April 5, 2016 /PRNewswire/-- Greenphire, the global leader in clinical payment solutions, today announced that it has made more than 3 million patient reimbursements through its ClinCard solution, automating payments of more than $200 million to clinical trial participants around the world. According to the Center for Information and Study on Clinical Research Participation (CISCRP), the top factor that motivates study volunteers to continue to participate in a clinical research study is compensation. Greenphire's ClinCard is the only patented payment technology designed to simplify clinical trial reimbursement and provide a patient-centric experience.
03/12/16 12:04 PMNIVALIS THERAPEUTICS, INC. Financials -
03/08/16 04:03 PMNIVALIS THERAPEUTICS, INC. Files SEC form 10-K, Annual Report -
03/08/16 03:00 PMNivalis (NVLS) Provides Update on Cystic Fibrosis Candidate -
03/08/16 12:37 PMNivalis Therapeutics (NVLS) Expands N91115 Clinical Development Program in CF - Nivalis Therapeutics, Inc. (NASDAQ: NVLS) today announced the expansion of their clinical development plan for N91115, the Company’s lead investigational drug and first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR ...
03/07/16 03:05 PMNivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis - [GlobeNewswire] - Higher-dose arm initiated in ongoing Phase 2 study following safety review by independent Data Monitoring Committee. New Phase 2 study planned for patients who have one copy of the F508del-mutation and ...
03/02/16 07:00 AMNivalis Therapeutics to Present at Two Upcoming Investor Conferences - [Marketwired] - Nivalis Therapeutics, Inc. , a clinical stage pharmaceutical company focused on treating people with cystic fibrosis , today announced that Chief Executive Officer Jon Congleton will present a corporate ...
03/01/16 04:48 PMNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex -
03/01/16 03:05 PMNivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors - [GlobeNewswire] - BOULDER, Colo., March 01, 2016-- Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis, today announced that Paul ...
03/01/16 12:24 PMEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q4 Earnings Report - Below are the earnings highlights for Nivalis Therapeutics, Inc. (NVLS): -Earnings: -$6.56 million in Q4 vs. -$3.49 million in the same period last year. -EPS: -$0.42 in Q4 vs. -$1.58 in the same period last year.
02/29/16 06:07 PMNivalis Therapeutics reports 4Q loss -
02/29/16 03:05 PMNivalis Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results - [GlobeNewswire] - -Phase 2 Study Enrollment Progressing. -Orphan Drug and Fast Track Designations Granted for N91115 in Cystic Fibrosis. BOULDER, Colo., Feb. 29, 2016-- Nivalis Therapeutics, Inc., a clinical-stage pharmaceutical ...
02/20/16 11:52 AMNivalis Therapeutics, Inc. (NVLS) - Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product ...
02/19/16 12:20 PMNivalis Therapeutics (NVLS) Granted FDA Fast Track Status for N91115 in CF - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Nivalis Therapeutics, Inc. (NASDAQ: NVLS) announced the U.S. Food and Drug Administration has granted Fast Track designation for the Company’s lead investigational drug ...
02/18/16 04:11 PMApplied Materials, Nivalis & Nordstrom Lead Thursday's After-Hours Movers -
02/18/16 03:05 PMNivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic Fibrosis - [GlobeNewswire] - BOULDER, Colo., Feb. 18, 2016-- Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis, today announced the U.S. ...
02/16/16 10:36 AMWhat Vertex’s Results Mean for Corbus, ProQR, and Nivalis - [Accesswire] - NEW YORK, NY / ACCESSWIRE / February 16, 2016 / Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) was down by as much as 11.4% to $81.98 yesterday as investors were split on its earnings, reported after market ...
01/29/16 11:50 AMWhat's in Store for Nivalis (NVLS) this Earnings Season? - Nivalis Therapeutics, Inc. (NVLS - Snapshot Report) is expected to report fourth-quarter 2015 results on Feb 1. Last quarter, the company’s earnings were in line with expectations. Let’s see how things are shaping up for this announcement. Factors at ...
01/26/16 04:02 PMNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
01/18/16 01:55 PMNivalis' N91115 Gets Orphan Drug Status for Cystic Fibrosis -
01/18/16 11:20 AMNivalis CF drug gets FDA 'orphan drug' designation; stock rises Friday - Nivalis Therapeutics Inc. said the U.S. Food and Drug Administration has given its N91115 cystic fibrosis drug an "orphan drug" designation, and the company's shares soared in Friday trading. Boulder-based Nivalis (Nasdaq: NVLS) shares rose more than 15 ...
01/18/16 07:15 AMNivalis Therapeutics (NVLS) Jumps: Stock Moves Up 15.5% -
01/15/16 10:25 AMNivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis - [at noodls] - Designation Marks Important Milestone in the Development and Regulatory Pathway for the First CFTR Stabilizer BOULDER, Colo., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), ...
01/15/16 10:17 AM11:17 am Nivalis Therapeutics confirms being granted Orphan Designation by the FDA for N91115 in cystic fibrosis -
12/01/15 11:33 AMNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
12/01/15 06:23 AMNivalis Therapeutics Announces First Patient Dosed in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis - [at noodls] - Study Will Evaluate Efficacy and Safety of N91115, Data Expected in the Second Half of 2016 BOULDER, Colo., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage ...
11/25/15 01:02 PMIs Synthetic Biologics Inc (SYN) Going to Burn These Hedge Funds? -
11/23/15 07:25 AMMarket Data on Movers and Shakers - Research on Fenix Parts, Kirin International Holding, Nivalis Therapeutics and Sharps Compliance - [Accesswire] - NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Fenix Parts ...
11/10/15 06:16 AMNivalis Therapeutics to Present at the Stifel Healthcare Conference 2015 - [at noodls] - BOULDER, Colo., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today announced ...
11/03/15 04:04 PMNIVALIS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
11/02/15 04:03 PMNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
11/02/15 03:26 PMNivalis Therapeutics Reports Third Quarter and Nine-Month Financial Results for 2015 - [at noodls] - - N91115 Phase 1b Data Recently Presented at North American Cystic Fibrosis Conference - Phase 2 Study on Track to Enroll First Patient in Fourth Quarter BOULDER, Colo., Nov. 02, 2015 (GLOBE NEWSWIRE) ...

Social

About Nivalis Therapeutics

Nivalis Therapeutics logoNivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVLS
  • CUSIP:
Key Metrics:
  • Previous Close: $4.66
  • 50 Day Moving Average: $4.45
  • 200 Day Moving Average: $4.68
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $69.73M
  • Current Year EPS Consensus Estimate: $-2.17 EPS
  • Next Year EPS Consensus Estimate: $-2.95 EPS
Additional Links:
Nivalis Therapeutics (NASDAQ:NVLS) Chart for Monday, July, 25, 2016